Find Funding Opportunities

The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. Clinical Trials are not accepted under this NOFO.

This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

The purpose of this Notice of Funding Opportunity (NOFO) is toinvite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVIDProject).TheNeuroCOVIDProject was establishedin 2020 to serve as a robust national resource to understand theneurological complicationsassociated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications ofCOVID-19 by using this de-identified database. Thedata may be combined with data from other U.S. and International databases for analyses.However,collection of new primary data from those affected by COVID-19 or comparison cohorts isNOT covered by this NOFO.

The purpose of this Funding Opportunity Announcement (FOA) is to support a Chemical Exposure Resource and Coordination Core (ExRC) that will provide infrastructure, management, and research support for studies of Chemicals of Concern (CoC) to the Chemical Countermeasures Research Program (CCRP). This core, established across diverse geographical regions, is intended to support multidisciplinary CCRP investigators, through development of infrastructure and exposure protocols for selected toxicants. The ExRC will provide facility access for using diverse models to characterize pathophysiological mechanisms and evaluating potential medical countermeasures through early-stage development efforts supported by the CCRP.

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

Goal is to have experimental models that can accurately reproduce neuropathological signatures and clinically relevant neurodegenerative, biochemical and behavioral sequelae as those seen in human subjects post-TBI AD/ADRDs. Requirement: Interdisciplinary Team science approach / consortium type of applications. Applications will include multiple sites (3-5 sites) developing and/or testing specific models that will then implement a test of reproducibility across the consortium. Requirement: Must have a clinician with expertise in post-TBI ADRD on the team. Encourage having neuropathologists as consultants on grants. Requirement: Models developed through this FOA will be required to share their model, model details and related standards with the VA-funded interagency preclinical resource center - PRECISE TBI Studies investigating neurodegeneration of white matter and chronic inflammation in post-TBI AD/ADRDs are highly encouraged. Innovative applications reaching beyond the current AD/ADRD models are highly encouraged.